您当前所在的位置:首页 > 产品中心 > 产品详细信息
154-42-7 分子结构
点击图片或这里关闭

2-amino-6,7-dihydro-3H-purine-6-thione

ChemBase编号:236
分子式:C5H5N5S
平均质量:167.1917
单一同位素质量:167.02656619
SMILES和InChIs

SMILES:
S=c1nc([nH]c2nc[nH]c12)N
Canonical SMILES:
Nc1nc(=S)c2c([nH]1)nc[nH]2
InChI:
InChI=1S/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)
InChIKey:
WYWHKKSPHMUBEB-UHFFFAOYSA-N

引用这个纪录

CBID:236 http://www.chembase.cn/molecule-236.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
2-amino-6,7-dihydro-3H-purine-6-thione
IUPAC传统名
thioguanine
商标名
Tabloid
Wellcome U3B
Lanvis
别名
TG
ThG
Tioguanine
Tioguanin
6-Thioguanine
6-Mercaptoguanine
6-Mercapto-2-aminopurine
2-Aminopurine-6-thiol
2-Aminopurine-6(1H)-thione
2-Aminopurin-6-thiol
2-Amino-6-purinethiol
2-Amino-6-merkaptopurin
2-Amino-6-mercaptopurine
2-Amino 6MP
Thioguanine
CAS号
154-42-7
PubChem SID
160963699
46508170
PubChem CID
2723601

数据来源

数据来源

所有数据来源 商品来源 非商品来源
数据来源 数据ID 价格
Selleck Chemicals
S1774 external link 加入购物车 请登录

理论计算性质

理论计算性质

JChem ALOGPS 2.1
Acid pKa 10.526401  质子受体
质子供体 LogD (pH = 5.5) -0.35059884 
LogD (pH = 7.4) -0.34978372  Log P -0.34946936 
摩尔折射率 46.892 cm3 极化性 16.556705 Å3
极化表面积 79.09 Å2 可自由旋转的化学键
里宾斯基五规则 true 
Log P -0.36  LOG S -2.3 
溶解度 8.34e-01 g/l 

分子性质

分子性质

理化性质 安全信息 产品相关信息 生物活性(PubChem)
溶解度
36.3 mg/mL expand 查看数据来源
疏水性(logP)
-0.7 expand 查看数据来源
保存条件
-20°C expand 查看数据来源
成盐信息
Free Base expand 查看数据来源

详细说明

详细说明

DrugBank DrugBank Selleck Chemicals Selleck Chemicals
DrugBank -  DB00352 external link
Item Information
Drug Groups approved
Description An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. [PubChem]
Indication For remission induction and remission consolidation treatment of acute nonlymphocytic leukemias.
Pharmacology Thioguanine is an antineoplastic anti-metabolite used in the treatment of several forms of leukemia including acute nonlymphocytic leukemia. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. Thioguanine was first synthesized and entered into clinical trial more than 30 years ago. It is a 6-thiopurine analogue of the naturally occurring purine bases hypoxanthine and guanine. Intracellular activation results in incorporation into DNA as a false purine base. An additional cytotoxic effect is related to its incorporation into RNA. Thioguanine is cross-resistant with mercaptopurine. Cytotoxicity is cell cycle phase-specific (S-phase).
Toxicity Oral, mouse: LD50 = 160 mg/kg. Symptoms of overdose include nausea, vomiting, malaise, hypotension, and diaphoresis.
Affected Organisms
Humans and other mammals
Biotransformation Hepatic. First converted to 6-thioguanilyic acid (TGMP). TGMP is further converted to the di- and tri-phosphates, thioguanosine diphosphate (TGDP) and thioguanosine triphosphate (TGTP) by the same enzymes that metabolize guanine nucleotides.
Absorption Absorption of an oral dose is incomplete and variable, averaging approximately 30% of the administered dose (range: 14% to 46%)
Half Life 80 minutes (range 25-240 minutes)
External Links
Wikipedia
RxList
Drugs.com
Selleck Chemicals -  S1774 external link
Research Area: Cancer
Biological Activity:
The thiopurine drugs are purine antimetabolites widely used in the treatment of acute lymphoblastic leukemia, autoimmune disorders (e.g., Crohn’s disease, rheumatoid arthritis) and organ transplant recipients. [1]

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • http://en.wikipedia.org/wiki/Thiopurine
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle